Dr. Reddy's Laboratories Ltd. (SSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Daptomycin for Injection, 500mg/vial single-dose vial, a therapeutic equivalent generic version of Cubicin® for Injection, approved by the U.S. Food and Drug Administration (USFDA).
The Cubicin® for Injection (daptomycin for injection) brand and generic had U.S. sales of approximately $640.8 million MAT for the most recent twelve months ending in March 2019 according to IQVIA Health*.
Dr. Reddy's Daptomycin for Injection is available in single-dose 15 ml vials containing 500 mg of daptomycin.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2812 as compared to the previous close of Rs. 2804.95. The total number of shares traded during the day was 14868 in over 1005 trades.
The stock hit an intraday high of Rs. 2826.1 and intraday low of 2765. The net turnover during the day was Rs. 41606176.
Cubicin is a trademark of Merck Sharp & Dahme Corp.